aTyr Pharma, Inc. (NASDAQ:LIFE) Forecasted to Earn Q1 2022 Earnings of ($0.44) Per Share

aTyr Pharma, Inc. (NASDAQ:LIFE) – Investment analysts at Piper Sandler issued their Q1 2022 earnings per share (EPS) estimates for shares of aTyr Pharma in a report released on Tuesday, September 21st. Piper Sandler analyst E. Tenthoff forecasts that the biotechnology company will earn ($0.44) per share for the quarter. Piper Sandler has a “Overweight” rating and a $19.00 price objective on the stock. Piper Sandler also issued estimates for aTyr Pharma’s Q2 2022 earnings at ($0.48) EPS, Q3 2022 earnings at ($0.48) EPS and Q4 2022 earnings at ($0.52) EPS.

Other equities research analysts have also issued reports about the stock. Roth Capital lifted their price target on shares of aTyr Pharma from $20.00 to $21.00 and gave the company a “buy” rating in a report on Monday, September 13th. Oppenheimer lifted their price target on shares of aTyr Pharma from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, September 14th. Zacks Investment Research lowered shares of aTyr Pharma from a “hold” rating to a “strong sell” rating in a report on Friday, August 13th. HC Wainwright lifted their price target on shares of aTyr Pharma from $13.00 to $18.00 and gave the company a “buy” rating in a report on Monday, September 13th. Finally, Jonestrading reiterated a “buy” rating and set a $15.00 target price on shares of aTyr Pharma in a research report on Wednesday, June 30th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, aTyr Pharma has an average rating of “Buy” and a consensus target price of $16.50.

Shares of aTyr Pharma stock opened at $12.48 on Thursday. The firm has a market capitalization of $211.16 million, a PE ratio of -5.43 and a beta of 2.00. The firm’s 50 day moving average is $5.87 and its 200 day moving average is $4.94. aTyr Pharma has a 1 year low of $2.93 and a 1 year high of $13.10.

aTyr Pharma (NASDAQ:LIFE) last released its earnings results on Monday, August 9th. The biotechnology company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.13). aTyr Pharma had a negative net margin of 155.18% and a negative return on equity of 75.60%.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC acquired a new position in shares of aTyr Pharma in the 2nd quarter worth approximately $148,000. Alyeska Investment Group L.P. increased its stake in shares of aTyr Pharma by 29.6% in the 2nd quarter. Alyeska Investment Group L.P. now owns 1,274,747 shares of the biotechnology company’s stock valued at $6,221,000 after acquiring an additional 291,153 shares in the last quarter. Telemetry Investments L.L.C. increased its stake in shares of aTyr Pharma by 51.7% in the 2nd quarter. Telemetry Investments L.L.C. now owns 179,308 shares of the biotechnology company’s stock valued at $875,000 after acquiring an additional 61,088 shares in the last quarter. State Street Corp bought a new stake in shares of aTyr Pharma in the 2nd quarter valued at $269,000. Finally, Northern Trust Corp increased its stake in shares of aTyr Pharma by 18.5% in the 2nd quarter. Northern Trust Corp now owns 26,105 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 4,072 shares in the last quarter. Hedge funds and other institutional investors own 40.89% of the company’s stock.

In other news, Director Paul Schimmel purchased 250,000 shares of the company’s stock in a transaction dated Monday, September 20th. The shares were purchased at an average price of $8.00 per share, for a total transaction of $2,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 5.14% of the stock is currently owned by insiders.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel immunological pathways. Its product pipeline include ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1;DARS-1(3). The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Featured Story: Trading Ex-Dividend Strategy

Earnings History and Estimates for aTyr Pharma (NASDAQ:LIFE)

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.